Literature DB >> 23256740

The search for animal models for Lassa fever vaccine development.

Igor S Lukashevich1.   

Abstract

Lassa virus (LASV) is the most prevalent arenavirus in West Africa and is responsible for several hundred thousand infections and thousands of deaths annually. The sizeable disease burden, numerous imported cases of Lassa fever (LF) and the possibility that LASV can be used as an agent of biological warfare make a strong case for vaccine development. Currently there is no licensed LF vaccine and research and devlopment is hampered by the high cost of nonhuman primate animal models and by biocontainment requirements (BSL-4). In addition, a successful LF vaccine has to induce a strong cell-mediated cross-protective immunity against different LASV lineages. All of these challenges will be addressed in this review in the context of available and novel animal models recently described for evaluation of LF vaccine candidates.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23256740      PMCID： PMC3564576          DOI： 10.1586/erv.12.139

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  135 in total

1.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity.

Authors:  Christian Klewitz; Hans-Dieter Klenk; Jan ter Meulen
Journal:  J Gen Virol       Date:  2007-08       Impact factor: 3.891

3.  Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts.

Authors:  M D Bowen; C J Peters; S T Nichol
Journal:  Mol Phylogenet Evol       Date:  1997-12       Impact factor: 4.286

4.  Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus.

Authors:  S M Buckley; J Casals
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

5.  Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever.

Authors:  S Mahanty; D G Bausch; R L Thomas; A Goba; A Bah; C J Peters; P E Rollin
Journal:  J Infect Dis       Date:  2001-05-11       Impact factor: 5.226

6.  Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.

Authors:  Marco A Goicochea; Juan C Zapata; Joseph Bryant; Harry Davis; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2012-01-09       Impact factor: 3.641

Review 7.  Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of virus-host interaction.

Authors:  Stefan Kunz
Journal:  Virology       Date:  2009-03-25       Impact factor: 3.616

8.  Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation.

Authors:  Igor S Lukashevich; Ilia Tikhonov; Juan D Rodas; Juan C Zapata; Yida Yang; Mahmoud Djavani; Maria S Salvato
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Novel arenavirus, Zambia.

Authors:  Akihiro Ishii; Yuka Thomas; Ladslav Moonga; Ichiro Nakamura; Aiko Ohnuma; Bernard Hang'ombe; Ayato Takada; Aaron Mweene; Hirofumi Sawa
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

10.  Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Mark G Lewis; Joan B Geisbert; Allen Grolla; Anders Leung; Jason Paragas; Lennox Matthias; Mark A Smith; Steven M Jones; Lisa E Hensley; Heinz Feldmann; Peter B Jahrling
Journal:  PLoS Pathog       Date:  2008-11-28       Impact factor: 6.823
View more
  16 in total

1.  Case Report: Imported Case of Lassa Fever - New Jersey, May 2015.

Authors:  Prathit A Kulkarni; Debra Chew; Manal Youssef-Bessler; Hanaa A Hamdi; Lindsay A Montoya; Kimberly B Cervantes; Nicole L Mazur; Diana Lucas; Julia W Wells; David Cennimo; Anne Sutherland; Linda M Di Domenico; Lincoln P Miller; Frantz Pierre-Louis; Gregory Rokosz; Atif Nazir; Marie A de Perio; Luis Lowe; Craig Manning; Kenneth R Mead; Bryan E Christensen; César G Albariño; Ute Ströher; Maleeka Glover; Edward I Lifshitz; Christina G Tan; Pierre E Rollin; Shereen Semple
Journal:  Am J Trop Med Hyg       Date:  2018-10       Impact factor: 2.345

Review 2.  Inhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses.

Authors:  Bjoern Meyer; Hinh Ly
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

3.  Characterization of the host response to pichinde virus infection in the Syrian golden hamster by species-specific kinome analysis.

Authors:  Shane Falcinelli; Brian B Gowen; Brett Trost; Scott Napper; Anthony Kusalik; Reed F Johnson; David Safronetz; Joseph Prescott; Victoria Wahl-Jensen; Peter B Jahrling; Jason Kindrachuk
Journal:  Mol Cell Proteomics       Date:  2015-01-08       Impact factor: 5.911

4.  A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.

Authors:  David Safronetz; Chad Mire; Kyle Rosenke; Friederike Feldmann; Elaine Haddock; Thomas Geisbert; Heinz Feldmann
Journal:  PLoS Negl Trop Dis       Date:  2015-04-17

Review 5.  Human hemorrhagic Fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis.

Authors:  Junjie Shao; Yuying Liang; Hinh Ly
Journal:  Pathogens       Date:  2015-05-21

Review 6.  Innate immune response to arenaviral infection: a focus on the highly pathogenic New World hemorrhagic arenaviruses.

Authors:  Takaaki Koma; Cheng Huang; Olga A Kolokoltsova; Allan R Brasier; Slobodan Paessler
Journal:  J Mol Biol       Date:  2013-09-26       Impact factor: 5.469

7.  Novel mechanism of arenavirus-induced liver pathology.

Authors:  Juliane I Beier; Jenny D Jokinen; Gretchen E Holz; Patrick S Whang; Amah M Martin; Nikole L Warner; Gavin E Arteel; Igor S Lukashevich
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

8.  A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.

Authors:  Kathleen A Cashman; Eric R Wilkinson; Carl I Shaia; Paul R Facemire; Todd M Bell; Jeremy J Bearss; Joshua D Shamblin; Suzanne E Wollen; Kate E Broderick; Niranjan Y Sardesai; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2017-10-18       Impact factor: 3.452

9.  Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever.

Authors:  Lisa Oestereich; Anja Lüdtke; Paula Ruibal; Elisa Pallasch; Romy Kerber; Toni Rieger; Stephanie Wurr; Sabrina Bockholt; José V Pérez-Girón; Susanne Krasemann; Stephan Günther; César Muñoz-Fontela
Journal:  PLoS Pathog       Date:  2016-05-18       Impact factor: 6.823

10.  Development of real-time reverse transcriptase qPCR assays for the detection of Punta Toro virus and Pichinde virus.

Authors:  Christopher P Stefan; Kitty Chase; Susan Coyne; David A Kulesh; Timothy D Minogue; Jeffrey W Koehler
Journal:  Virol J       Date:  2016-03-31       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.